cardiovascular agents

Summary

Summary: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.

Top Publications

  1. ncbi Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II
    C Riccioni
    Complex Unit of Angiology, Nuovo Regina Margherita Hospital, Rome, Italy
    Int Angiol 27:253-9. 2008
  2. ncbi European guidelines on cardiovascular disease prevention in clinical practice: executive summary
    Ian Graham
    Department of Cardiology, The Adelaide and Meath Hospital, Dublin, Ireland
    Eur Heart J 28:2375-414. 2007
  3. ncbi Eplerenone in patients with systolic heart failure and mild symptoms
    Faiez Zannad
    INSERM, Centre d Investigation Clinique 9501 and Unité 961, and the Department of Cardiology, Nancy University, Nancy, France
    N Engl J Med 364:11-21. 2011
  4. ncbi Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
    Giorgia De Berardis
    Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Via Nazionale 8 A, 66030 S Maria Imbaro, Italy
    BMJ 339:b4531. 2009
  5. ncbi Drug-eluting stent fracture: incidence, contributing factors, and clinical implications
    Timothy Canan
    Division of Cardiology, David Geffen School of Medicine at University of California, Los Angeles, California, USA
    Catheter Cardiovasc Interv 75:237-45. 2010
  6. ncbi Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial
    Bruce L Wilkoff
    The Cleveland Clinic Foundation, 9500 Euclid Ave, Desk F 15, Cleveland, OH 44195, USA
    JAMA 288:3115-23. 2002
  7. ncbi Treatment of patent ductus arteriosus
    Jonathan Wyllie
    The James Cook University Hospital, Marton Road, Middlesbrough TS4 3BW, UK
    Semin Neonatol 8:425-32. 2003
  8. ncbi ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise th
    Jeffrey L Anderson
    J Am Coll Cardiol 50:e1-e157. 2007
  9. ncbi Ranolazine: a review of its use in chronic stable angina pectoris
    M Asif A Siddiqui
    Adis International Limited, Auckland, New Zealand
    Drugs 66:693-710. 2006
  10. ncbi Pharmacological activity of cardiovascular agents from herbal medicine
    John W Ho
    Department of Biochemistry, The Chinese University of Hong Kong, Shatin, Hong Kong
    Cardiovasc Hematol Agents Med Chem 5:273-7. 2007

Research Grants

  1. Organic Nitrate Metabolism, Tolerance and Action
    Ho Leung Fung; Fiscal Year: 2010
  2. Pharmacogenetics and Cardiovascular Events
    Bruce Psaty; Fiscal Year: 2006
  3. Impact of Medicaid Policy on cardiovascular drug use and clinical outcomes
    Michael A Fischer; Fiscal Year: 2010
  4. Organic Nitrate Metabolism, Tolerance and Action
    Ho Leung Fung; Fiscal Year: 2007
  5. Atrial natriuretic peptide receptor crystallization
    Focco van den Akker; Fiscal Year: 2004
  6. Coupling mechanisms of OP4 receptor and calcium channels
    Victor Ruiz Velasco; Fiscal Year: 2006
  7. eNOS Polymorphisms, Aging and Platelet Function
    Jane Freedman; Fiscal Year: 2005
  8. Inhibitors of PAR1-G13 Interface for Arthersclerosis
    Annette Gilchrist; Fiscal Year: 2002
  9. Genetic Mechanisms of Anthracycline Cardiotoxicity in Pediatric Cancer Survivors
    Steven Lipshultz; Fiscal Year: 2007
  10. PEDIATRIC CARDIOMYOPATHY REGISTRY
    Steven Lipshultz; Fiscal Year: 2000

Detail Information

Publications268 found, 100 shown here

  1. ncbi Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II
    C Riccioni
    Complex Unit of Angiology, Nuovo Regina Margherita Hospital, Rome, Italy
    Int Angiol 27:253-9. 2008
    ..PLC is involved in cellular metabolism and is transformed into two active substances, free L-carnitine and propionyl-coenzyme A in the mitochondria, which take part in fatty acid transfer and in the citric acid cycle, respectively...
  2. ncbi European guidelines on cardiovascular disease prevention in clinical practice: executive summary
    Ian Graham
    Department of Cardiology, The Adelaide and Meath Hospital, Dublin, Ireland
    Eur Heart J 28:2375-414. 2007
  3. ncbi Eplerenone in patients with systolic heart failure and mild symptoms
    Faiez Zannad
    INSERM, Centre d Investigation Clinique 9501 and Unité 961, and the Department of Cardiology, Nancy University, Nancy, France
    N Engl J Med 364:11-21. 2011
    ..We evaluated the effects of eplerenone in patients with chronic systolic heart failure and mild symptoms...
  4. ncbi Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
    Giorgia De Berardis
    Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Via Nazionale 8 A, 66030 S Maria Imbaro, Italy
    BMJ 339:b4531. 2009
    ..To evaluate the benefits and harms of low dose aspirin in people with diabetes and no cardiovascular disease...
  5. ncbi Drug-eluting stent fracture: incidence, contributing factors, and clinical implications
    Timothy Canan
    Division of Cardiology, David Geffen School of Medicine at University of California, Los Angeles, California, USA
    Catheter Cardiovasc Interv 75:237-45. 2010
    ..Other complications observed with stent fracture include stent thrombosis, coronary aneurysms, myocardial infarction, and sudden death...
  6. ncbi Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial
    Bruce L Wilkoff
    The Cleveland Clinic Foundation, 9500 Euclid Ave, Desk F 15, Cleveland, OH 44195, USA
    JAMA 288:3115-23. 2002
    ..Most currently implanted ICD devices provide dual-chamber pacing therapy. The most common comorbid cause for mortality in this population is congestive heart failure...
  7. ncbi Treatment of patent ductus arteriosus
    Jonathan Wyllie
    The James Cook University Hospital, Marton Road, Middlesbrough TS4 3BW, UK
    Semin Neonatol 8:425-32. 2003
    ..PDA closure can then be achieved using medical means, with surgery reserved for patients in whom this fails or in whom there are contra-indications. However, the optimum timing for intervention remains unknown...
  8. ncbi ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise th
    Jeffrey L Anderson
    J Am Coll Cardiol 50:e1-e157. 2007
  9. ncbi Ranolazine: a review of its use in chronic stable angina pectoris
    M Asif A Siddiqui
    Adis International Limited, Auckland, New Zealand
    Drugs 66:693-710. 2006
    ..Nevertheless, ranolazine ER may well prove to be a useful alternative and adjunct to conventional haemodynamic antianginal therapy in the treatment of chronic stable angina...
  10. ncbi Pharmacological activity of cardiovascular agents from herbal medicine
    John W Ho
    Department of Biochemistry, The Chinese University of Hong Kong, Shatin, Hong Kong
    Cardiovasc Hematol Agents Med Chem 5:273-7. 2007
    ..The study will provide insights into drug action and demonstrate the therapeutic benefits of herbal medicine for the treatment of cardiovascular disease...
  11. ncbi Pharmacotherapy according to treatment guidelines is associated with lower mortality in a community-based sample of patients with chronic heart failure: a prospective cohort study
    Stefan Störk
    Department of Internal Medicine I Center for Cardiovascular Medicine, University of Wurzburg, Klinikstrasse 6 8, D 97070 Wurzburg, Germany
    Eur J Heart Fail 10:1236-45. 2008
    ..The effectiveness of chronic heart failure (CHF) pharmacotherapy in unselected cohorts is unknown...
  12. ncbi Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography
    Rory Hachamovitch
    Department of Imaging, Cedars-Sinai Medical Center, University of California Los Angeles School of Medicine, Los Angeles, Calif 90048, USA
    Circulation 107:2900-7. 2003
    ..These findings have significant consequences for future approaches to post-single photon emission computed tomography patient management if confirmed by prospective evaluations...
  13. ncbi Propionyl-L-carnitine in Leriche-Fontaine stage II peripheral arterial obstructive disease
    Claudio Allegra
    San Giovanni Hospital, Rome, Italy
    Ann Vasc Surg 22:552-8. 2008
    ..From these preliminary data has emerged an indication of therapy with PLC for chronic obstructive arteriopathy of the lower limbs at stage II. Further studies with higher numbers of patients and more controlled variables are planned...
  14. ncbi Methods for identifying cardiovascular agents: a review
    David Anthony Tulis
    Cardiovascular Disease Research Program, J L Chambers Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, NC 27707, USA
    Recent Pat Cardiovasc Drug Discov 1:47-56. 2006
    ..The invention disclosed in Methods for identifying cardiovascular agents [1] provides screening methods which can be used to identify certain suspected cardiovascular agents that ..
  15. ncbi Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study
    Chiara Melloni
    Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA
    Expert Rev Cardiovasc Ther 6:9-16. 2008
    ....
  16. ncbi Telmisartan prevents cardiovascular events in a broad group of at-risk patients
    Magnus Baumhakel
    University Hospital of the Saarland, Department of Cardiology, Homburg Saar, Germany
    Expert Opin Pharmacother 10:3113-7. 2009
    ..In these patients who are intolerant to ACE-Is or who do not achieve blood pressure control, the ARB with the best evidence for secondary prevention is telmisartan according to the results of the ONTARGET trial...
  17. ncbi Systems biology approaches to the study of cardiovascular drugs
    Yuri Nikolsky
    GeneGo, Inc, St Joseph, MI, USA
    Methods Mol Biol 662:221-43. 2010
    ..All relevant steps, for example, experimental design, tissue collection and high quality RNA preparation, bioinformatical analysis of functional processes, and pathways (targeted and untargeted) are addressed...
  18. ncbi Ranolazine (Ranexa) in the treatment of chronic stable angina
    Sajid Aslam
    Division of Cardiovascular Medicine, University Hospital, Nottingham, UK
    Adv Ther 27:193-201. 2010
    ..This review provides an insight into this treatment option, describes the clinical trials evidence, proposed mechanism of action, and pharmacokinetics, and outlines the indications for its use in chronic stable angina...
  19. ncbi ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999
    Elliott M Antman
    Circulation 110:588-636. 2004
  20. ncbi The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment
    M Komajda
    Eur Heart J 24:464-74. 2003
    ..The survey also identifies several important factors including age, gender, type of hospital ward, co morbid factors which influence the prescription of heart failure medication at discharge...
  21. ncbi Oral omega n3-PUFA therapy (Omacor) has no impact on indices of heart rate variability in stable post myocardial infarction patients
    Ali Hamaad
    University Department of Medicine, City Hospital, Dudley Road, Birmingham, England, UK
    Cardiovasc Drugs Ther 20:359-64. 2006
    ..CONCLUSIONS: Three month supplementation of omega 3 PUFA (Omacor) 1 g/day has no effect on HRV is patients post AMI...
  22. ncbi Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology
    Karl Swedberg
    , Department of Medicine, Sahlgrenska University Hospital, Sweden
    Eur Heart J 26:1115-40. 2005
  23. ncbi Neuropsychiatric effects of cardiovascular drug therapy
    Seth Keller
    Department of Medicine, Division of Cardiology, Beth Israel Medical Center, New York, New York 10595, USA
    Cardiol Rev 11:73-93. 2003
    ..Since neuropsychiatric symptoms are seen in patients with cardiovascular disease, clinicians should be aware of the possible relationship between these symptoms and concurrent cardiovascular drug therapy...
  24. ncbi Antianginal efficacy of omapatrilat in patients with chronic angina pectoris
    Bernard R Chaitman
    Saint Louis University School of Medicine, St Louis, Missouri 63117, USA
    Am J Cardiol 95:1283-9. 2005
    ..The data confirm the proof of principle that broader vasopeptidase inhibition beyond angiotensin-converting enzyme inhibition is required to alleviate symptoms of chronic angina...
  25. ncbi Adherence in heart failure in the elderly: problem and possible solutions
    Martje H L van der Wal
    Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands
    Int J Cardiol 125:203-8. 2008
    ..Non-adherence to this regimen is a problem in many heart failure patients, leading to worsening symptoms, rehospitalization and decreased quality of life...
  26. ncbi 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to devel
    Theodore D Fraker
    J Am Coll Cardiol 50:2264-74. 2007
  27. ncbi Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy
    Risto S Cvetkovic
    Adis International Limited, Auckland, New Zealand
    Drugs 65:1005-24. 2005
    ..01). Dexrazoxane is the only cardioprotective agent with proven efficacy in cancer patients receiving anthracycline chemotherapy and is a valuable option for the prevention of cardiotoxicity in this patient population...
  28. ncbi Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial
    David A Morrow
    TIMI Study Group, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, Mass 02115, USA
    JAMA 297:1775-83. 2007
    ..Ranolazine is a novel antianginal agent that reduces ischemia in patients with chronic angina but has not been studied in patients with acute coronary syndromes (ACS)...
  29. ncbi Does ranolazine have a place in the treatment of acute coronary syndromes?
    L Kristin Newby
    JAMA 297:1823-5. 2007
  30. ncbi Neuropsychiatric consequences of cardiovascular medications
    Jeff C Huffman
    Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
    Dialogues Clin Neurosci 9:29-45. 2007
    The use of cardiovascular medications can have a variety of neuropsychiatric consequences. Many cardiovascular agents cause higher rates of fatigue and sedation than placebo, and case reports of medication-induced mood syndromes, ..
  31. ncbi The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia
    Steven E Lipshultz
    Department of Pediatrics, University of Miami School of Medicine, Holtz Children s Hospital of the University of Miami Jackson Memorial Medical Center and the Sylvester Comprehensive Cancer Center, Miami 33101, USA
    N Engl J Med 351:145-53. 2004
    ..Doxorubicin chemotherapy is very effective in children with acute lymphoblastic leukemia (ALL) but also injures myocardial cells. Dexrazoxane, a free-radical scavenger, may protect the heart from doxorubicin-associated damage...
  32. ncbi Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise
    Robinson Joannides
    Department of Pharmacology, Rouen University Hospital, INSERM U644, Rouen, France
    Br J Clin Pharmacol 61:127-37. 2006
    ....
  33. ncbi Suboptimal use of cardioprotective drugs in newly treated elderly individuals with type 2 diabetes
    Caroline Sirois
    Faculty of Pharmacy, Laval University, Quebec, Canada
    Diabetes Care 30:1880-2. 2007
  34. ncbi Late stent thrombosis: considerations and practical advice for the use of drug-eluting stents: a report from the Society for Cardiovascular Angiography and Interventions Drug-eluting Stent Task Force
    John McB Hodgson
    St. Joseph's Hospital and Medical Center, 350 West Thomas Road, Phoenix, AZ 85013, USA
    Catheter Cardiovasc Interv 69:327-33. 2007
  35. ncbi The initial management of stable angina in Europe, from the Euro Heart Survey: a description of pharmacological management and revascularization strategies initiated within the first month of presentation to a cardiologist in the Euro Heart Survey of Stab
    Caroline A Daly
    Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK
    Eur Heart J 26:1011-22. 2005
    ....
  36. ncbi NO/redox disequilibrium in the failing heart and cardiovascular system
    Joshua M Hare
    Johns Hopkins University School of Medicine, Department of Medicine, Cardiology Division, Baltimore, Maryland 21205, USA
    J Clin Invest 115:509-17. 2005
    ....
  37. ncbi Ranolazine and other antianginal therapies in the era of the drug-eluting stent
    Peter Berger
    JAMA 291:365-7. 2004
  38. ncbi Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial
    Bernard R Chaitman
    Department of Medicine, Division of Cardiology, St Louis University School of Medicine, St Louis, MO, USA
    JAMA 291:309-16. 2004
    ....
  39. ncbi Subacute cardiotoxicity caused by anthracycline therapy in children: can dexrazoxane prevent this effect?
    Gabor T Kovacs
    Haemato oncology Division, 2nd Department of Pediatrics, Semmelweis University, Tuzolto 7 9, 1094, Budapest, Hungary
    Eur J Pediatr 166:1187-8. 2007
  40. ncbi Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction
    Eric Bates
    Duke Clinical Research Institute, 2400 Pratt St, Room 7035, Durham, NC 27705
    Circulation 117:886-96. 2008
    ..KAI-9803, a delta-protein kinase C inhibitor, has been shown to ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI)...
  41. ncbi Time dependent vascular and myocardial responses of a second generation, small vessel, paclitaxel-eluting stent platform
    Craig A Thompson
    Cardiology Section, Dartmouth Hitchcock Medical Center, Dartmouth Medical School, Lebanon, New Hampshire, USA
    Catheter Cardiovasc Interv 73:597-604. 2009
    ..The purpose of this study was to evaluate the time-dependent vascular and myocardial responses to a second-generation, small vessel (< or =2.5 mm) paclitaxel-eluting stent (PES) platform...
  42. ncbi Metabolic manipulation in ischaemic heart disease, a novel approach to treatment
    Leong Lee
    Wales Heart Research Institute, Heath Park, Cardiff, CF14 4XN, UK
    Eur Heart J 25:634-41. 2004
    ..They offer significant promise for the treatment of symptoms occurring due to inoperable aortic stenosis, hypertrophic cardiomyopathy, and chronic heart failure...
  43. ncbi Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview
    Louis J Ignarro
    Nitric Oxide Research Group, Molecular and Medical Pharmacology, Center for the Health Sciences, University of California, Los Angeles, USA
    Circ Res 90:21-8. 2002
    ..Here, we review these classes of agents, summarizing their fundamental chemistry and pharmacology, and provide an overview of their cardiovascular mechanisms of action...
  44. ncbi Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease
    Bart Staels
    Department of Atherosclerosis, Institut Pasteur de Lille, UMR545 Inserm, University of Lille 2, Lille, France
    Nat Clin Pract Cardiovasc Med 5:542-53. 2008
    ....
  45. ncbi The challenge of polypharmacy in cardiovascular medicine
    Massimo Volpe
    Cardiology Department, IInd School of Medicine, University of Rome Sapienza, S Andrea Hospital, Rome, Italy
    Fundam Clin Pharmacol 24:9-17. 2010
    ..However, large randomized trials are required to define its impact on clinical outcomes. This review will focus on challenges of polypharmacy in CV medicine, illustrating potential options to face this emerging crisis...
  46. ncbi Expanded use of the TAXUS Express Stent: two-year safety insights from the 7,500 patient ARRIVE Registry programme
    John M Lasala
    Washington University School of Medicine, St Louis, MO 63110, USA
    EuroIntervention 5:67-77. 2009
    ..We report 2-year outcomes in a large unselected drug-eluting stent population (N=7,492) in the TAXUS Express2 ARRIVE post-market surveillance programme (101 U.S. sites)...
  47. ncbi Aspirin for prevention of cardiovascular events
    William R Hiatt
    BMJ 337:a1806. 2008
  48. ncbi Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial
    Jean Claude Tardif
    Montreal Heart Institute, Universite de Montreal, Montreal, Quebec, Canada
    Eur Heart J 30:540-8. 2009
    ..To evaluate the anti-anginal and anti-ischaemic efficacy of the selective I(f) current inhibitor ivabradine in patients with chronic stable angina pectoris receiving beta-blocker therapy...
  49. ncbi Loss of cardioprotection with ageing
    Kerstin Boengler
    Institut fur Pathophysiologie, Universitatsklinikum Essen, Hufelandstrasse 55, 45122 Essen, Germany
    Cardiovasc Res 83:247-61. 2009
    ..g. ischaemic pre and postconditioning in aged organs and animals will be discussed, and the development of strategies aimed to antagonize the age-induced loss of protection will be addressed...
  50. ncbi Vascular disease in the metabolic syndrome: do we need to target the microcirculation to treat large vessel disease?
    Andrew J Krentz
    Institute of Developmental Sciences, School of Medicine, University of Southampton, Southampton General Hospital, Southampton, UK
    J Vasc Res 46:515-26. 2009
    ..The hypothesis that vascular events can be prevented, or at least deferred, through earlier therapeutic intervention in pre-diabetic subjects with glucose intolerance is amenable to testing in clinical trials...
  51. ncbi New strategies for improving heart failure management: a primary care perspective
    J Basile
    Primary Care Division, Ralph H Johnson VA Medical Center, Charleston, SC 29403, USA
    South Med J 94:166-74. 2001
    ..Digoxin may be added to therapy for patients with persistent symptoms or rapid atrial fibrillation. Clinical trials have shown that such combination regimens reduce the risk of hospitalization and death in patients with heart failure...
  52. ncbi Metabolic therapeutics in angina pectoris: history revisited with perhexiline
    Sally Inglis
    Faculty of Health Sciences, University of Queensland, Australia
    Eur J Cardiovasc Nurs 5:175-84. 2006
    ..This review aims to update the cardiac nurse with knowledge to manage the care a patient receiving perhexiline maleate treatment and provide a brief review of three new metabolic agents: trimetazidine, ranolazine and etomoxir...
  53. ncbi Atrial fibrillation and dementia in a population-based study. The Rotterdam Study
    A Ott
    Department of Epidemiology and Biostatistics, Erasmus University Medical School, Rotterdam, The Netherlands
    Stroke 28:316-21. 1997
    ..We investigated the association of atrial fibrillation with dementia and cognitive impairment in a large cross-sectional, population-based study in the elderly...
  54. ncbi Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment
    Leong Lee
    Department of Cardiology, University of Nottingham, Queens Medical Centre, Nottingham, England
    Circulation 112:3280-8. 2005
    ..Perhexiline may therefore represent a novel treatment for CHF with a good safety profile, provided that the dosage is adjusted according to plasma levels...
  55. ncbi Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up
    Lubomir Elbl
    Department of Cardiopulmonary Testing, University Hospital Brno, Jihlavska 20, Brno, 62500, Czech Republic
    Support Care Cancer 14:128-36. 2006
    ..The authors conducted a retrospective study to determine whether dexrazoxane (ICRF-187) would reduce late anthracycline-induced cardiotoxicity in patients treated in childhood for hematological malignancy...
  56. ncbi Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology
    Frans Van de Werf
    Cardiology, Gasthuisberg University Hospital, Leuven, Belgium
    Eur Heart J 24:28-66. 2003
  57. ncbi Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients
    Lubomir Elbl
    Department of Cardiology, University Hospital Brno, Jihlavska 20, 62500 Brno, Czech Republic
    Eur J Pediatr 164:678-84. 2005
    ..CONCLUSION: Dexrazoxane seems to reduce the risk of late subclinical cardiotoxicity. Dexrazoxane-treated patients revealed better exercise tolerance; however the haemodynamic response to the stress was no different in both sub-groups...
  58. ncbi Stent fracture, an incidental finding or a significant marker of clinical in-stent restenosis?
    Fareed Shaikh
    Cardiovascular Disease Section, Aurora Sinai Aurora St Luke s Medical Centers, University of Wisconsin School of Medicine and Public Health Milwaukee Clinical Campus, Milwaukee, Wisconsin, USA
    Catheter Cardiovasc Interv 71:614-8. 2008
    ..The predictors and clinical significance for stent fracture (SF) in drug-eluting stents (DES) remain unknown. We identified procedural factors leading to SF and its clinical consequences in DES...
  59. ncbi Structure of recombinant human renin, a target for cardiovascular-active drugs, at 2.5 A resolution
    A R Sielecki
    Department of Biochemistry, University of Alberta, Edmonton, Canada
    Science 243:1346-51. 1989
    ..Knowledge of the actual structure, as opposed to the use of models based on related enzymes, should facilitate the design of renin inhibitors...
  60. ncbi Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology
    Michel Ovize
    Service d Explorations Fonctionnelles Cardiovasculaires and Inserm U886, Hospices Civils de Lyon, University of Lyon, France
    Cardiovasc Res 87:406-23. 2010
    ....
  61. ncbi Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine
    Markus Jerling
    Clinical Pharmacology, CV Therapeutics, Palo Alto, CA, USA
    Clin Pharmacol Ther 78:288-97. 2005
    ..No serious adverse events were observed in the study...
  62. ncbi Management of heart failure in primary health care. A retrospective study on electronic patient records in a registered population
    Gunnar Nilsson
    Department of Clinical Science, Karolinska Institutet, Stockholm, Sweden
    Scand J Prim Health Care 20:161-5. 2002
    ..To study the prevalence, patient characteristics and management of patients with heart failure, and the feasibility of using everyday electronic patient records for research...
  63. ncbi Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina
    Jean Claude Tardif
    Montreal Heart Institute, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada
    Eur Heart J 26:2529-36. 2005
    ..Ivabradine has shown anti-ischaemic and anti-anginal activity in a placebo-controlled trial. The objective of this study was to compare the anti-anginal and anti-ischaemic effects of ivabradine and the beta-blocker atenolol...
  64. ncbi Long-term outcomes of bifurcation lesions after implantation of drug-eluting stents with the "mini-crush technique"
    Alfredo R Galassi
    Department of Internal Medicine and Systemic Disease, Clinical Division of Cardiology, Ferrarotto Hospital, University of Catania, Italy
    Catheter Cardiovasc Interv 69:976-83. 2007
    ..To evaluate clinical and angiographic long-term outcome of "the mini-crush" technique for treating bifurcation lesions...
  65. ncbi Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease
    Whady Hueb
    Heart Institute of the University of Sao Paulo, Sao Paulo, Brazil
    Circulation 115:1082-9. 2007
    ....
  66. ncbi Sustained increased risk of adverse cardiac events over 5 years after implantation of gold-coated coronary stents
    Jürgen Pache
    Deutsches Herzzentrum, Lazarettstr 36, 80636 München, Germany
    Catheter Cardiovasc Interv 68:690-5. 2006
    ..To study the 5-year outcome of patients treated with gold-coated stent placement...
  67. ncbi Factors predictive of cardiac events and restenosis after sirolimus-eluting stent implantation in small coronary arteries
    Cheol Whan Lee
    Department of Medicine, Asan Medical Center, University of Ulsan, Seoul, Korea
    Catheter Cardiovasc Interv 69:821-5. 2007
    ..Predictors of cardiac events and restenosis after sirolimus-eluting stent (SES) implantation in small coronary arteries were evaluated...
  68. ncbi [Interactions between cardiovascular drugs and anesthesia and surgery]
    Pierre Albaladejo
    Service d Anesthésie Réanimation SAMU SMUR 94, Hopital Henri Mondor, Creteil
    Presse Med 35:1697-702. 2006
    ..Interruption of antiplatelet agents appears to be associated with a risk of arterial thrombosis in patients with coronary conditions, notably those with conventional stents and most especially those with drug-eluting stents...
  69. ncbi Improved survival with drug-eluting stent implantation in comparison with bare metal stent in patients with severe left ventricular dysfunction
    Giuseppe Gioia
    Atlantic City Medical Center, Pomona, New Jersey 08240, USA
    Catheter Cardiovasc Interv 68:392-8. 2006
    ....
  70. ncbi [Drugs used in cardiovascular diseases and cytokines]
    Dariusz Andrzejczak
    Z Zakładu Farmakodynamiki Uniwersytetu Medycznego w Lodzi
    Wiad Lek 59:232-7. 2006
    ..In the paper the influence of statins, fibrates, angiotensin converting enzyme inhibitors (ACEI), beta-blockers, calcium channel blockers and phosphodiesterase inhibitors on the activity of cytokines was introduced...
  71. ncbi Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry
    John A Spertus
    MPH, Mid America Heart Institute, 4401 Wornall Rd, Kansas City, MO 64111
    Circulation 113:2803-9. 2006
    ..The rate and consequences of prematurely discontinuing thienopyridine therapy after DES placement for acute myocardial infarction (MI) are unknown...
  72. ncbi Practical algorithms for pharmacologic management of the post myocardial infarction patient
    James A Reiffel
    Cardiology Division, Department of Medicine, Columbia University, New York, New York, USA
    Clin Cardiol 28:I28-37. 2005
    ..Current guidelines also recommend that patients post MI with elevated cholesterol levels should be prescribed lipid therapy with a statin at hospital discharge...
  73. ncbi Reducing the risks of sudden death and heart failure post myocardial infarction: utility of optimized pharmacotherapy
    Jonathan Sackner-Bernstein
    Clin Cardiol 28:I19-27. 2005
    ....
  74. ncbi Impact of renal insufficiency on clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus-eluting stents
    Gaku Nakazawa
    Division of Cardiology, Mitsui Memorial Hospital, Chiyoda ku, Tokyo, Japan
    Catheter Cardiovasc Interv 69:808-14. 2007
    ..Sirolimus-eluting stents (SES) have been demonstrated to reduce restenosis. However, there have been few studies evaluating the impact of renal insufficiency on the angiographic as well as clinical outcomes after SES implantation...
  75. ncbi Randomized comparative trial of a thin-strut bare metal cobalt-chromium stent versus a sirolimus-eluting stent for coronary revascularization
    Paolo Ortolani
    Institute of Cardiology, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Catheter Cardiovasc Interv 69:790-8. 2007
    ..To see whether use of a sirolimus-eluting stent (SES) is superior to a third-generation thin-strut, cobalt-chromium stent (CCS) in terms of in-segment late loss at 9 months in patients with symptomatic coronary artery disease...
  76. ncbi Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
    Richard B Devereux
    Greenberg Division of Cardiology, Weill Medical College of Cornell University, New York, NY 10021, USA
    Curr Med Res Opin 23:443-57. 2007
    ....
  77. ncbi Restenosis following thin-strut bare-metal stents versus thick-strut drug-eluting stents
    David J Moliterno
    Catheter Cardiovasc Interv 69:799-800. 2007
  78. ncbi Comparison between sirolimus- and paclitaxel-eluting stents in complex patient and lesions subsets
    Probal Roy
    Division of Cardiology, Washington Hospital Center, Washington DC 20010, USA
    Catheter Cardiovasc Interv 70:167-72. 2007
    ..The data for more complex subsets of patients and lesions remains conflicting. This study aimed to compare SES with PES in a selected population with a broad range of complex features...
  79. ncbi Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents
    Cheol Whan Lee
    Department of Medicine, Asan Medical Center, University of Ulsan, Seoul, Korea
    Catheter Cardiovasc Interv 71:594-8. 2008
    ..Sirolimus-eluting stents have been increasingly used for treatment of restenosis after implantation of bare metal stents (BMSs) or drug-eluting stents (DESs), but little is known regarding their long-term outcomes...
  80. ncbi Treatment of drug-eluting stent restenosis: a sandwich may not be the best combo
    Jorge Belardi
    Catheter Cardiovasc Interv 71:599. 2008
  81. ncbi Survival advantage in Medicare patients receiving drug-eluting stents compared with bare metal stents: real or artefactual?
    Fen Wei Wang
    Division of Cardiology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA
    Catheter Cardiovasc Interv 71:636-43. 2008
    ..We evaluated mortality in the first year after implantation of DES, specifically the sirolimus-eluting stent (SES), Cypher vs. BMS in "real world" older patients using the Medicare claims database...
  82. ncbi DES editorial. Is there a survival benefit?
    Dr Martyn Thomas
    Catheter Cardiovasc Interv 71:644-5. 2008
  83. ncbi Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis
    Soko Setoguchi
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02120, USA
    J Am Coll Cardiol 51:1247-54. 2008
    ..We sought to assess the relationship between increasing use of cardiovascular medications and trends in long-term prognosis after myocardial infarction (MI) in the elderly...
  84. ncbi Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart
    Matteo Anselmino
    University Department of Cardiology, San Giovanni Battista Molinette Hospital, Turin, Italy
    Eur J Cardiovasc Prev Rehabil 15:216-23. 2008
    ..This report compares the impact of EBM and revascularization on mortality and cardiovascular events (CVE=mortality, myocardial infarction or stroke) in CAD patients with and without DM...
  85. ncbi Stenting for unprotected left main coronary artery stenosis: a further step
    Y Cottin
    Arch Cardiovasc Dis 101:7-8. 2008
  86. ncbi Clinical and angiographic results of angioplasty with a paclitaxel-eluting stent for unprotected left main coronary artery disease (a study of 101 consecutive patients)
    R Cherradi
    Fédération de cardiologie, Pôle cardiovasculaire et métabolique, CHU Rangueil, Toulouse, France
    Arch Cardiovasc Dis 101:11-7. 2008
    ..After coronary stenting with drug eluting stents, long-term clinical outcome of unprotected left main coronary artery disease is unknown, even large scale registries or randomised trials with coronary artery bypass graft are ongoing...
  87. ncbi Long-term clinical outcomes of real-world experience using sirolimus-eluting stents in saphenous vein graft disease
    Ravi K Ramana
    Division of Cardiology, Loyola University Medical Center, Maywood, Illinois, USA
    Catheter Cardiovasc Interv 71:886-93. 2008
    ..Specifically, we compared clinical endpoints of patients who received sirolimus-eluting stents (SES) versus bare-metal stents (BMS) for SVG disease...
  88. ncbi Drug-eluting stent in saphenous vein graft lesions
    Ran Kornowski
    Catheter Cardiovasc Interv 71:894-5. 2008
  89. ncbi The role of percutaneous revascularization for renal artery stenosis
    Gregory J Dubel
    Department of Diagnostic Imaging, Brown University Medical School, Division of Interventional Radiology, Providence, Rhode Island 02903, USA
    Vasc Med 13:141-56. 2008
    ..Until the CORAL trial results are in, physicians will continue to be faced with difficult choices when determining the optimal management for RAS patients and deciding which, if any, patients should be offered revascularization...
  90. ncbi Does the preventive effect of different drugs depend on location of the atherosclerotic process?
    P Poredos
    Department of Vascular Diseases, University Medical Center Ljubljana, Slovenia
    Int Angiol 27:274-80. 2008
    ....
  91. ncbi Highlights of the 56th annual scientific session of the American College of Cardiology
    X Rabasseda
    Prous Science Medical Information Department, Prous Science
    Timely Top Med Cardiovasc Dis 11:E12. 2007
  92. ncbi Cardiovascular protection paradigms: is change on the horizon?
    Vasilios Papademetriou
    Department of Veterans Affairs and Georgetown University Medical Centers, Washington, DC, USA
    Rev Cardiovasc Med 8:200-13. 2007
    ..Such changes should be considered in the design of new clinical trials and in the interpretation of current data...
  93. ncbi Late medical versus interventional therapy for stable ST-segment elevation myocardial infarction
    Sammy Elmariah
    Mount Sinai Medical Center, New York, NY, USA
    Nat Clin Pract Cardiovasc Med 5:42-52. 2008
    ....
  94. ncbi Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation
    Young Hoon Jeong
    Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, 388 1 Poongnap dong, Songpa Gu, Seoul, 138 736, Republic of Korea
    Int J Cardiol 125:36-40. 2008
    ..Whether drug-eluting stents (DES) can reduce long-term clinical events in CKD patients compared with bare metal stents (BMS) has not been established...
  95. ncbi Medical management of abdominal aortic aneurysm
    J Golledge
    Vascular Biology Unit, School of Medicine, James Cook University, Townsville, Australia 4811
    Eur J Vasc Endovasc Surg 34:267-73. 2007
    ..Medical management also is required to reduce peri-operative risks and stabilise endovascular aneurysm repair. Whilst some of the therapies targeting cardiovascular risk reduction may be helpful, other emerging strategies are discussed...
  96. ncbi Treatment of unprotected left main disease with drug-eluting stents in patients at high risk for coronary artery bypass grafting
    Peter Barlis
    Department of Cardiology, Austin Hospital, Melbourne, Victoria 3084, Australia
    Cardiovasc Revasc Med 8:84-9. 2007
    ..Recently, drug-eluting stents (DES) have reduced instent restenosis after PCI, but their role in the treatment of left main disease remains unclear...
  97. ncbi Comparison of drug-eluting stents with bare metal stents in unselected patients with acute myocardial infarction
    L Iri Kupferwasser
    Division of Cardiology, Cedars Sinai Medical Center, University of California, Los Angeles School of Medicine, California 90048, USA
    Catheter Cardiovasc Interv 70:1-8. 2007
    ..The aim of this study was to compare the procedural characteristics and outcomes of patients with acute myocardial infarction treated with drug-eluting stents (DES) vs. bare metal stents (BMS)...
  98. ncbi Revascularization in severe left ventricular dysfunction: outcome comparison of drug-eluting stent implantation versus coronary artery by-pass grafting
    Giuseppe Gioia
    Atlantic City Medical Center, Pomona, NJ 08240, USA
    Catheter Cardiovasc Interv 70:26-33. 2007
    ....
  99. ncbi Three-year follow-up of the first prospective randomized comparison between paclitaxel and sirolimus stents: the TAXi-LATE trial
    Alexandre Berger
    Service of Cardiology, Clinic Cecil, Lausanne, Switzerland
    Catheter Cardiovasc Interv 70:163-6. 2007
    ..Analysis of the 3-year outcome of the original population of the TAXi trial which compared the efficacy of the paclitaxel (PES) and the sirolimus (SES) stents in a randomized "real world" investigation...
  100. ncbi Incidence and predictors of clinically driven target lesion revascularization from bare-metal stents to drug-eluting stents
    Seung-Jung Park
    Catheter Cardiovasc Interv 70:184. 2007
  101. ncbi Pharmacological interventions for peripheral artery disease
    Daniel A Duprez
    University of Minnesota, Cardiovascular Division, Medical School, VCRC Room 270, Minneapolis, MN 55455, USA
    Expert Opin Pharmacother 8:1465-77. 2007
    ..New developments should focus on improvement of endothelial function, vascular repair and enhancement of collateral circulation...

Research Grants92

  1. Organic Nitrate Metabolism, Tolerance and Action
    Ho Leung Fung; Fiscal Year: 2010
    ..believe that our studies can provide new and meaningful data that will contribute to the establishment of a unifying mechanism for organic nitrate action and deleterious effects, and lead to their better therapeutic use ..
  2. Pharmacogenetics and Cardiovascular Events
    Bruce Psaty; Fiscal Year: 2006
    ..The primary defense is replication: we would therefore welcome collaboration from others in the Pharmacogenetics Network in validation efforts. ..
  3. Impact of Medicaid Policy on cardiovascular drug use and clinical outcomes
    Michael A Fischer; Fiscal Year: 2010
    ....
  4. Organic Nitrate Metabolism, Tolerance and Action
    Ho Leung Fung; Fiscal Year: 2007
    ..We believe that our studies can provide new and meaningful data that will contribute to the establishment of a unifying mechanism for organic nitrate action and deleterious effects, and lead to their better therapeutic use ..
  5. Atrial natriuretic peptide receptor crystallization
    Focco van den Akker; Fiscal Year: 2004
    ..Our long term structural studies on the molecular mechanism of ANP receptor signaling could enhance the development of renal and cardiovascular drugs. ..
  6. Coupling mechanisms of OP4 receptor and calcium channels
    Victor Ruiz Velasco; Fiscal Year: 2006
    ..to clarify the signaling mechanisms underlying these processes and facilitate the development of novel cardiovascular agents for treating hypertension resulting from increased sympathetic tone...
  7. eNOS Polymorphisms, Aging and Platelet Function
    Jane Freedman; Fiscal Year: 2005
    ..We have continued to examine the imoortance of this mutation to the vascular response. ..
  8. Inhibitors of PAR1-G13 Interface for Arthersclerosis
    Annette Gilchrist; Fiscal Year: 2002
    ..Hundreds of billions of dollars are spent each year treating heart disease. In 1998, it was estimated that sales of cardiovascular drugs alone were $37 billion. ..
  9. Genetic Mechanisms of Anthracycline Cardiotoxicity in Pediatric Cancer Survivors
    Steven Lipshultz; Fiscal Year: 2007
    ..If the HFE mutations are related to increased cardiotoxicity of anthracyclines. This study will elucidate the molecular mechanisms of anthracycline cardiotoxicity in pediatric ALL cancer survivors. ..
  10. PEDIATRIC CARDIOMYOPATHY REGISTRY
    Steven Lipshultz; Fiscal Year: 2000
    ..The registry should lead to definitive understanding of the pathogenesis of these disorders and offer the hope to have a major clinical impact on the clinical practice of medicine in this area. ..
  11. PEDIATRIC CARDIOMYOPATHY REGISTRY
    Steven Lipshultz; Fiscal Year: 2007
    ..These studies will dramatically increase our understanding of pediatric cardiomyopathy, suggest new areas of research and improved patient management. ..
  12. HAART Associated Cardiotoxicity in HIV-Infected Children
    Steven Lipshultz; Fiscal Year: 2007
    ..The findings will help determine the need for cardiovascular follow-up, prevention and therapeutic trials. ..
  13. PEDIATRIC CARDIOMYOPATHY REGISTRY
    Steven Lipshultz; Fiscal Year: 2003
    ..abstract_text> ..
  14. Plasminogen activators and NMDA after brain injury
    William Armstead; Fiscal Year: 2009
    ..Immunohistochemistry, detection of plasminogen activator and MAPK expression, and CBF determination by radiolabled microspheres will be performed. ..
  15. Plasminogen activators and NMDA after brain injury
    William M Armstead; Fiscal Year: 2010
    ..Immunohistochemistry, detection of plasminogen activator and MAPK expression, and CBF determination by radiolabled microspheres will be performed. ..
  16. POTASSIUM CHANNELS AND CEREBRAL HEMODYNAMICS AFTER BRAIN
    William Armstead; Fiscal Year: 2005
    ..These studies may lead to therapies for brain injured children. ..
  17. Plasminogen activators and cerebral ischemic injury
    William M Armstead; Fiscal Year: 2010
    ....
  18. Plasminogen activators and cerebral ischemic injury
    William Armstead; Fiscal Year: 2007
    ....
  19. PATHOGENESIS OF TRANSPLANT ASSOCIATED ARTERIOSCLEROSIS
    Peter Libby; Fiscal Year: 2002
    ..The observations point to distinct mechanisms mediating acute vs. chronic allograft pathologies, and suggest that different therapeutic interventions will be uniquely applicable to each. ..
  20. REDUCTION OF TRIGLYCERIDES IN WOMEN ON HRT
    Lewis Kuller; Fiscal Year: 2005
    ..NMR spectroscopy of lipoproteins, inflammatory markers, and estrogen metabolites will also be evaluated. Therefore, the primary goal of this trial is the modification of measures of subclinical disease among HRT users. ..
  21. EPIDEMIOLOGY OF CARDIOVASCULAR RISK FACTORS IN WOMEN
    Lewis Kuller; Fiscal Year: 2002
    ..They further note that the identification of early and modifiable risk factors for subclinical disease should lead to prevention or reduction of clinical cardiovascular disease among postmenopausal women. ..
  22. Cytokines and Sympathetic Activation in Heart Failure
    Robert Felder; Fiscal Year: 2006
    ..These studies will provide new insights into the role of the pro-imflammatory cytokines in heart failure, perhaps leading to new therapeutic strategies. ..
  23. Northeast Ohio Center for Cardiovascular Cell Therapy Research
    Stephen Ellis; Fiscal Year: 2007
    ..End of Abstract) ..